This observational study aimed to identify predictors of kinesiophobia and examine its correlation with early functional outcomes in TKA recipients. On the first and fifth postoperative days (POD1 and POD5), we evaluated pain using the International Pain Outcomes Questionnaire (IPO-Q) and created multidimensional pain composite scores (PCSs). The Total Pain Composite Score (PCStotal) assesses the overall impact of pain, taking into account outcomes of pain intensity, pain-related interference with function, and emotions and side effects. Functional status on POD 5 was determined by the Barthel index, 6 min walking test, and knee range of motion. Kinesiophobia was assessed on POD5 using the Tampa Scale for Kinesiophobia (TSK). Among 75 TKA patients, 27% exhibited kinesiophobia. The final regression model highlighted PCStotal on POD5 (OR = 6.2, CI = 1.9–19.9), PCStotal (OR = 2.1, CI = 1.2–3.8) on POD1, and the intensity of chronic pain before surgery (OR = 1.4, CI = 1.1–2.1) as significant kinesiophobia predictors. On POD5, those with kinesiophobia showed increased dependency, slower gait, and poorer knee extension recovery. This study emphasizes the need to identify and address kinesiophobia in TKA patients for better functional outcomes and recovery. Additionally, it is vital to assess different domains of pain, not just pain intensity, as it can lead to kinesiophobia development.

Background and Objectives: Idiopathic anterior knee pain is a common condition in adolescents and is mostly of unknown cause. The aim of this study was to examine the influence of the Q-angle and muscle strength on idiopathic anterior knee pain. Materials and Methods: Seventy-one adolescents (41 females and 30 males) diagnosed with anterior knee pain were included in this prospective study. The extensor strength in the knee joint and the Q-angle were monitored. The healthy extremity was used as a control. The Student’s paired sample t-test was applied for testing the difference. Statistical significance was set at 0.05. Results: There was no statistically significant difference in the Q-angle value between the idiopathic AKP and the healthy extremity (p > 0.05) within the entire sample. A statistically significant higher Q-angle of the idiopathic AKP knee (p < 0.05) was obtained in the female subgroup. No statistically significant difference (p > 0.05) was found in the male subgroup. Within the male subgroup, the strength of the extensors within the knee joint of the healthy extremity had statistically significant higher values than the strength of these muscles in the affected extremity (p < 0.05). Conclusion: A greater Q-angle is a risk factor linked to anterior knee pain within the female population. Decreased muscle strength of knee joint extensors is a risk factor linked to anterior knee pain in both sex subgroups.

Background and Objectives: A bone–patellar tendon–bone (BTB) autograft in anterior cruciate ligament reconstruction (ACLR) is still considered the gold standard among many orthopedic surgeons, despite anterior knee pain and kneeling pain being associated with bone defects at the harvest site. Bioregenerative products could be used to treat these defects, perhaps improving both the postoperative discomfort and the overall reconstruction. Materials and methods: During a year-long period, 40 patients were enrolled in a pilot study and divided into a study group, in which bone defects were filled with Vivostat^® PRF (platelet-rich fibrin), and a standard group, in which bone defects were not filled. The main outcome was a decrease in the height and width of the bone defects, as determined by magnetic resonance imaging on the control exams during the one-year follow-up. The secondary outcomes included an evaluation of kneeling pain, measured with a visual analog scale (VAS), and an evaluation of the subjective knee scores. Results: The application of Vivostat^® PRF resulted in a more statistically significant reduction in the width of the defect compared with that of the standard group, especially at 8 and 12 months post operation (p < 0.05). Eight months following the surgery, the study group’s anterior knee pain intensity during kneeling was statistically considerably lower than that of the standard group (p < 0.05), and the statistical difference was even more obvious (p < 0.01) at the last follow-up. Each control examination saw a significant decrease in pain intensity in both the groups, with the values at each exam being lower than those from the prior exam (p < 0.01). A comparison of subjective functional test results 12 months post operation with the preoperative ones did not prove a statistically significant difference between the groups. Conclusions: The use of Vivostat^® PRF reduces kneeling pain and accelerates the narrowing of bone defects after ACLR with a BTB graft, but without confirmation of its influence on the subjective knee score.

Background and Objectives: Despite the high rate of donor site morbidity, a bone–patellar tendon–bone (BPTB) graft remains the gold standard when choosing a graft for anterior cruciate ligament (ACL) reconstruction. Damage to the infrapatellar branch of the saphenous nerve (IPBSN) during graft harvesting results in sensory deficits. Despite its high occurrence in the postoperative period, many patients go untreated, leading to a lower quality of life and potential professional impairment. The aim of this study was to assess the effectiveness of PRF therapy in alleviating sensory deficits and enhancing sensory nerve function in patients who have undergone BTB ACL reconstruction. Materials and Methods: This study was registered at ClinicalTrials.gov (Name of registry: ClinicalTrials.gov; Trial registration number: NCT07257666; Date of registration: 2 December 2025; Study start date: 7 January 2022). Over a one-year period, the pilot study enrolled 53 patients, treated them with BPTB ACL reconstruction, and divided them into two groups. The testing group’s donor site and subcutaneous tissue were treated with Vivostat^® PRF, whereas the standard group’s donor site and subcutaneous tissue remained untreated. The primary outcome measured was a reduction in the subjective numbness, which was tested during follow-up checks. Secondary outcomes included the evaluation of subjective knee scores for functional recovery, reported by the patients on control exams. Results: The use of Vivostat^® PRF resulted in a statistically significant reduction in sensory deficit among the groups at eight months (p < 0.05) and twelve months (p < 0.01) following surgery, favoring the testing group. The most substantial decrease in symptomatic patients was observed between four and eight months post-surgery, with no statistically significant difference found between the eight- and twelve-month follow-ups (p > 0.05). Evaluations of subjective knee function and activity scores showed no statistically significant differences between the groups. Conclusions: Using Vivostat^® PRF helps reduce sensory impairment in the area and minimizes donor site morbidity after BPTB ACL reconstruction.